Tomasz Kurek
Medical University of Silesia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tomasz Kurek.
American Journal of Cardiology | 2010
Tomasz Kurek; Radosław Lenarczyk; Jacek Kowalczyk; Andrzej Świątkowski; Oskar Kowalski; Joanna Stabryła-Deska; Grzegorz Honisz; Andrzej Lekston; Zbigniew Kalarus; T Kukulski
The significance of anemia in patients with acute myocardial infarction (AMI) treated with percutaneous coronary intervention (PCI) remains controversial. The aim of the present study was to evaluate the effect of anemia on the short- and long-term prognosis of patients with AMI treated with PCI, including high-risk subgroups. The study group consisted of 1,497 consecutive patients with AMI treated in the acute phase with PCI. Anemia was defined using World Health Organization criteria (hemoglobin level <13 g/dl for men and <12 g/dl for women). The study population was divided into 2 major groups (patients with [n = 248, 16.6%] and without [n = 1,249, 83.4%] anemia) and 6 subgroups (diabetes mellitus, impaired renal function, age >70 years, left ventricular dysfunction, incomplete revascularization, and multivessel disease). A comparative analysis was performed between both groups within the whole population and within the particular subgroups. Significantly greater 30-day (13.2% vs 7.3%), 1-year (20.5% vs 11.3%), and total (24.1% vs 12.7%; all p <0.05) mortality rates were observed in the anemic group. Multivariate analysis identified anemia as an independent predictor of any-cause death in the whole population during the observation period (covariate-adjusted hazard ratio 1.46, 95% confidence interval 1.31 to 1.61, p <0.05). Anemia was significantly associated with excessive long-term mortality in the multivessel disease group (adjusted hazard ratio 1.54, 95% confidence interval 1.34 to 1.74) and in the incomplete revascularization group (hazard ratio 1.67, both p <0.05). In conclusion, anemia on admission in patients with AMI treated in the acute phase with PCI was independently associated with increasing short- and long-term mortality, especially in the subgroups with incomplete revascularization and multivessel disease.
Nephron Clinical Practice | 2010
Jacek Kowalczyk; Paweł Francuz; Ryszard Swoboda; Radosław Lenarczyk; Beata Sredniawa; Adam Golda; Tomasz Kurek; Michal Mazurek; Tomasz Podolecki; Lech Poloński; Zbigniew Kalarus
Aim: This study evaluated the impact of hyperuricemia (HUR) on outcome in patients with different types of impaired renal function (IRF) and acute myocardial infarction (AMI) treated invasively. Methods: Out of 3,593 consecutive AMI patients treated invasively, 1,015 IRF patients were selected. The IRF group consisted of patients with baseline kidney dysfunction (BKD group) and/or patients with contrast-induced nephropathy (CIN group). HUR was defined as a serum uric acid concentration (SUAC) >420 µmol/l (>7 mg/dl). Independent predictors of death and major adverse cardiovascular events (MACE) were selected by the multivariate Cox-regression model. Results: Remote mortality rates were higher in HUR patients: IRF (32.7 vs. 18.6%), BKD (41.3 vs. 25.9%), CIN (35.4 vs. 16.7%); all p < 0.001. HUR was an independent predictor of death in BKD (hazard ratio (HR) 1.38, p < 0.05). Each 100-µmol/l increase in SUAC was associated with a significant increase of HR for mortality: 1.087 in IRF patients, 1.108 in BKD patients, 1.128 in CIN patients; all p < 0.05. Remote major adverse cardiovascular event rates were higher in HUR patients: IRF (55.4 vs. 48.9%), CIN (56.8 vs. 48%); both p < 0.05. Conclusions: In AMI patients treated invasively, an increase in SUAC is an independent predictor of death within all types of renal dysfunction; HUR defined as SUAC >420 µmol/l (>7 mg/dl) is a predictor only in BKD patients.
American Journal of Cardiology | 2012
Tomasz Podolecki; Radosław Lenarczyk; Jacek Kowalczyk; Tomasz Kurek; Joanna Boidol; Piotr Chodór; Andrzej Swiatkowski; Beata Sredniawa; Lech Poloński; Zbigniew Kalarus
To assess the incidence of atrial fibrillation (AF) and the clinical impact of AF types on outcomes in patients with acute myocardial infarction (AMI) treated invasively, we analyzed 2,980 consecutive patients with AMI admitted to our department from 2003 through 2008. Data collected by the insurer were screened to identify patients who died during the median follow-up of 41 months. AF was recognized in 282 patients (9.46%, AF group); the remaining 2,698 patients (90.54%) were free of this arrhythmia (control group). The AF group was divided into 3 subgroups: prehospital paroxysmal AF (n = 92, 3.09%), new-onset AF (n = 109, 3.66%), and permanent AF (n = 81, 2.72%). In-hospital and long-term mortalities were significantly higher (p <0.001 for the 2 comparisons) in the AF than in the control group (14.9% vs 5.3%, 37.2% vs 17.0%, respectively). Long-term mortality was significantly higher (p <0.001 for the 2 comparisons) in the new-onset AF (35.8%) and permanent AF (54.3%) groups than in the control group but did not differ significantly between the prehospital AF and control groups (21.7% vs 17.0%, p = NS). Considering types of arrhythmia separately, only permanent AF (hazard ratio 2.59) was an independent risk factor for death in the studied population. In conclusion, AF occurs in 1 of 10 patients with AMI treated invasively, with nearly equal distributions among prehospital, new-onset, and permanent forms. Although arrhythmia is a marker of worse short- and long-term outcomes, only permanent AF is an independent predictor for death in this population.
Catheterization and Cardiovascular Interventions | 2011
Michal Mazurek; Jacek Kowalczyk; Radosław Lenarczyk; Andrzej Swiatkowski; Oskar Kowalski; Agnieszka Sędkowska; Tomasz Was; Marcin Swierad; Patrycja Pruszkowska-Skrzep; Tomasz Kurek; Ewa Jedrzejczyk; Lech Poloński; Zbigniew Kalarus
Objectives: To compare the impact of the efficacy of percutaneous coronary intervention (PCI) on prognosis in ST and non‐ST elevation myocardial infarction (STEMI and NSTEMI) patients with respect to infarct‐related artery (IRA). Background: The significance of the efficacy of PCI in STEMI and NSTEMI depending on the type of IRA has yet to be clarified. Methods: Study population consisted of 2,179 STEMI and 554 NSTEMI consecutive patients treated with urgent PCI. The efficacy of PCI (TIMI [thrombolysis in myocardial infarction] 3 vs. TIMI < 3) was assessed with regard to the type of IRA (left anterior descending artery, circumflex artery [Cx] or right coronary artery). The mean follow‐up was 37.5 months. Results: The rate of unsuccessful PCI was similar in STEMI and NSTEMI irrespectively of IRA (14.1 vs. 17.7%; P = 0.062). In STEMI, unsuccessful PCI was associated with significantly higher early (23.1 vs. 5.6%; P < 0.001) and late (29.9 vs. 12.8%; P < 0.001) mortality regardless of IRA. In NSTEMI, the inefficacious PCI significantly increased early (19.0% vs. 0.9%; P < 0.001) and late (27.3% vs. 6.3%; P < 0.001) mortality only in patients with Cx‐related infarction. Unsuccessful PCI of IRA was an independent risk factor for death in STEMI (HR 1.64; P < 0.05), but not in NSTEMI (P = 0.64). Further analysis showed that whilst unsuccessful PCI of any vessel in STEMI is an independent risk factor for death, in NSTEMI this applies to unsuccessful PCI of Cx only. Conclusions: The significance of unsuccessful PCI of IRA seems to be different in STEMI and NSTEMI. Unsuccessful PCI is an independent risk factor for death in STEMI regardless of IRA and in NSTEMI with the involvement of Cx.
Cardiology Journal | 2009
Piotr Chodór; Hubert Krupa; Tomasz Kurek; Adam Sokal; Marcin Świerad; Tomasz Wąs; Witold Streb; Agata Duszańska; Andrzej Świątkowski; Grzegorz Honisz; Zbigniew Kalarus
Kardiologia Polska | 2011
Piotr Chodór; Tomasz Kurek; Anetta M. Kowalczuk; Marcin Świerad; Tomasz Wąs; Grzegorz Honisz; Andrzej Świątkowski; Witold Streb; Zbigniew Kalarus
Kardiologia Polska | 2007
Jacek Kowalczyk; Radosław Lenarczyk; Oskar Kowalski; Andrzej Świątkowski; Joanna Stabryła-Deska; Tomasz Kurek; Grzegorz Honisz; Tomasz Kukulski; Mariusz Gąsior; Zbigniew Kalarus
Cardiology Journal | 2007
Patrycja Pruszkowska-Skrzep; Sławomir Pluta; Anna Lenarczyk; Oskar Kowalski; Radosław Lenarczyk; Tomasz Kurek; Alina Zdrzałek-Skiba; Beata Chodór; Bożena Zeifert; Małgorzata Szkutnik; Jacek Białkowski; Zbigniew Kalarus
Advances in Interventional Cardiology | 2010
Anetta M. Kowalczuk; Piotr Chodór; Witold Streb; Tomasz Kurek; Zbigniew Kalarus; Marian Zembala
Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine | 2014
Agnieszka Sędkowska; Jacek Kowalczyk; Aleksandra Woźniak; Tomasz Kurek; Teresa Zielińska; Krzysztof Strojek; Janusz Gumprecht; Zbigniew Kalarus